Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773422 · ClinicalTrials.gov registry record · Phase 2
The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse
A Phase 2 study of Smoking, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00773422: Completed Phase 2 study of Smoking, sponsored by Yale University.
NCT00773422 is a Phase 2 study of Smoking that has completed, run by Yale University. The registered enrollment target is 30 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00773422, a Phase 2 study of Smoking, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine how medications thought to attenuate the effects of alcohol (naltrexone) and smoking cessation medications (varenicline) affect the ability to resist smoking and also subsequent ad-lib smoking, following a low-dose alcohol priming drink, in non-treatment seeking alcohol-drinking daily smokers.
Primary Outcome
Time to smoking during the smoking delay task. Smoking delay task occurred on day 8 of the study. Range of time delay is 0 minutes to 50 minutes.
Conditions Studied
Interventions
- DRUG placebo
- DRUG varenicline
- DRUG naltrexone
Study Locations (1)
Connecticut
- Yale Center for Clinical Investigation, Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT00773422 record still lists
NCT00773422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00773422 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00773422 about?
NCT00773422 is a clinical study titled "The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse". The purpose of this study is to examine how medications thought to attenuate the effects of alcohol (naltrexone) and smoking cessation medications (varenicline) affect the ability to resist smoking and also subsequent ad-lib smoking, following a low-dose alcohol priming drink, in non-treatment seeki...
What is the current status of trial NCT00773422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-01. Estimated completion is 2016-11.
What conditions does trial NCT00773422 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT00773422?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG), naltrexone (DRUG).
Who is sponsoring clinical trial NCT00773422?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773422 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00773422's enrollment target sits among peer trials
30 111th of 123 higher than 12 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
RECRUITING · Phase 2
-
App for Reducing Cravings to Smoke
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia